Issued on behalf of Conexeu Sciences Inc.

A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world‘s largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.

Equity Insider Market Commentary

TAMPA, Fla., June 2, 2026 /PRNewswire/ — For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don’t restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy each year choose not to pursue reconstruction at all. [2] When the menu is limited to foreign-body replacement, a large share of patients simply walk away.

Conexeu Sciences Inc. (NASDAQ: CNXU) is wagering that the next chapter is restoration rather than replacement — giving the body a temporary scaffold and the biological cues to rebuild its own tissue, then having that scaffold dissolve. The company began trading on the Nasdaq on May 21, 2026, with 25,269,996 shares issued and outstanding and 35,238,222 on a fully diluted basis; H.C. Wainwright & Co. acted as exclusive financial advisor on the listing. [3] Six days later, it gave investors a more concrete reason to look closely than most preclinical names ever offer. [1]

The Signal: Who Agreed to Test the Science

On May 27, Conexeu announced it had initiated a preclinical development program for its B.R.E.A.S.T.™ matrix — the most visible application of its proprietary CXU™ platform — at the Wake Forest Institute for Regenerative Medicine (WFIRM), part of Wake Forest University School of Medicine and Advocate Health. [1] WFIRM is one of the largest regenerative-medicine institutes in the world, with more than 500 researchers working across over 40 tissues and organs. The bridge into the institute runs through ReMDO, a 501(c)(3) non-profit set up specifically to de-risk regenerative-medicine technologies and speed their translation toward the clinic. [1]

The program will run on WFIRM’s Integrated Tissue-Organ Printing System (iTOPS), among the more advanced bioprinting platforms operating anywhere, and will evaluate three properties of the 3D-printed B.R.E.A.S.T.™ matrix: durability under physiological conditions, host-tissue integration, and resorbability over time. Those findings are intended to inform the design of future studies and guide the path toward clinical investigation. [1]

“Access to world-class tools at WFIRM … gives us both the scientific rigor and the infrastructure to develop our 3D-printed matrix responsibly, and to build the evidence base that future clinical investigation will require,” Conexeu stated in its release. [1] The candor cuts against the usual preclinical hype: the claim is not that the device works, but that a serious institution agreed to find out.

A Platform Story, Not a Single Product

B.R.E.A.S.T.™ is the headline, but Conexeu’s thesis rests on the platform beneath it. CXU™ is an extracellular-matrix technology that management describes by a single structural principle: one formula, one device, designed to scale across multiple addressable markets without reformulation. [2] The company is targeting wound care, dental applications, and facial and body contouring — including GLP-1–driven loose skin — with further expansion into 3d bioprinting workflows and veterinary use. [2]

The lead device candidate is Ten Minute Tissue™, an ECM-based product engineered to stay fluid at room temperature and set into a stable gel at body temperature in roughly ten minutes. In preclinical work it has shown organized scaffold formation, a favorable inflammatory profile, and support for cell migration, proliferation, and new tissue formation. [2] The intellectual-property position is unusually clean for an early-stage biotech: issued patents across the U.S., E.U., Japan, and Australia, with further filings pending, and full ownership with no royalty or licensing obligations. Management is pursuing a predicate-based U.S. regulatory route, targeting a 510(k) submission in early 2027 for its initial indication, subject to review. [2]

Two cautions belong in plain sight. CXU™ and B.R.E.A.S.T.™ are preclinical and investigational; safety and effectiveness have not been established, and the program has not been reviewed by the FDA. [2] And by the company’s own disclosure, none of its cited preclinical studies evaluated CXU™ specifically in breast tissue — breast reconstruction is the design-intent application, with breast-specific evidence still being developed. [2] Investors are buying a platform and a body of IP, not an approved product.

The Neighborhood: What Four Tissue Peers Just Reported

Conexeu is entering a market that is mid-transition, not uniformly booming — and the most recent earnings season makes that vivid. Four publicly traded tissue and regenerative-medicine names reported within the past few weeks, and they split cleanly between momentum and dislocation. That spread is the real backdrop for a preclinical entrant.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is the established regenerative-tissue operator of the group, spanning wound surgery, surgical reconstruction, and tissue repair. On May 5 it reported first-quarter 2026 revenue of $391.9 million, up 2.4%, with adjusted earnings of $0.54 per share versus $0.41 a year earlier — though on a GAAP basis it posted a $(0.06) per-share loss. Management reaffirmed revenue guidance and raised its full-year adjusted EPS range to $2.40–$2.50. [4] It is a picture of a mature franchise grinding out margin gains — the commercialized end of the spectrum Conexeu sits at the opposite pole of.

Bioventus Inc. (NASDAQ: BVS), a player in surgical solutions and restorative therapies, delivered the cleaner growth quarter. On May 6 it reported first-quarter revenue of about $132.1 million, up 7%, with adjusted EBITDA up 24% to roughly $24 million and adjusted EPS of $0.15, nearly double the prior year’s $0.08; the company raised its 2026 EPS and cash-flow guidance. [5] Bioventus shows what disciplined execution looks like in the active-healing segment when reimbursement is stable.

Organogenesis Holdings Inc. (NASDAQ: ORGO), a regenerative-medicine and tissue company focused on advanced wound care, illustrates the other side. On May 7 it reported first-quarter revenue of $36.3 million, down 58% year-over-year, driven by a 63% drop in advanced wound care; it posted a net loss of $(0.44) per share and cut full-year guidance to $270–$310 million. [6] Management tied the collapse to disruption and clinician confusion after Medicare withdrew local coverage determinations — a reminder that reimbursement policy, not science, can dominate a tissue company’s year. [6]

MiMedx Group, Inc. (NASDAQ: MDXG), which makes regenerative biologics from placental tissue, hit the same wall. On April 29 it reported first-quarter net sales of $59 million, down 33% year-over-year, with wound sales off 60% even as its surgical franchise grew 13%; it recorded a GAAP loss of $(0.07) per share and revised its 2026 outlook. [7] Like Organogenesis, MiMedx pinned the shortfall on the January Medicare reimbursement changes and inconsistent implementation across contractors. [7]

The takeaway is not that tissue regeneration is winning or losing — it is that the category is being reshaped in real time by reimbursement and execution, with established names landing on opposite sides of the same quarter. A preclinical company like Conexeu inherits both the long-term tailwind and that near-term turbulence.

What Turns a Listing Into a Thesis

CNXU is days old as a public company, with no revenue and a single preclinical platform. For a name like this, the meaningful signposts are scientific and regulatory, not financial: whether the WFIRM program produces data strong enough to justify clinical investigation, whether the early-2027 510(k) path holds, and whether the company can fund its programs — keeping in mind the direct listing raised no new capital. The broader regenerative-medicine market is projected to expand from roughly $47.4 billion in 2025 to about $230.4 billion by 2034, a tailwind that does not by itself de-risk any single platform. [13]

The bull case is a decade of university-derived IP, a platform aimed at several large markets at once, and a credentialed research partner willing to put the technology through its paces. The bear case is equally plain: one preclinical candidate, no finalized FDA pathway, no revenue, and a category currently being whipsawed by reimbursement policy. Both are true at once — which is why the right posture is to watch the bench at Wake Forest, not to anchor on a listing-day narrative.

CONTACT
Equity Insider  |  info@equity-insider.com  |  https://equity-insider.com | 604-265-2873

ARTICLE SOURCES

[1] Conexeu Sciences Inc. “Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine.” May 27, 2026.

[2] Conexeu Sciences Inc. / Newsfile Corp. “Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants.” May 19, 2026. newsfilecorp.com/release/297916

[3] Conexeu Sciences Inc. / Newsfile Corp. “Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol ‘CNXU.’” May 21, 2026. newsfilecorp.com/release/298401

[4] Integra LifeSciences Holdings Corporation. “Integra LifeSciences Reports First Quarter 2026 Financial Results.” May 5, 2026.

[5] Bioventus Inc. “Bioventus Reports First Quarter 2026 Financial Results.” May 6, 2026.

[6] Organogenesis Holdings Inc. “Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results.” May 7, 2026.

[7] MiMedx Group, Inc. “MIMEDX Announces First Quarter 2026 Operating & Financial Results.” April 29, 2026.

[13] Business Research Insights. “Regenerative Medicine Market Size, Share & Growth | CAGR of 19.2%.” Accessed May 2026.

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ“). MIQ has been paid a fee of $50,000 for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group (“CDMG“). There may be 3rd parties who may have shares of Conexeu Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision. The owner/operator of MIQ does not currently own any shares of Conexeu Sciences Inc. but reserves the right to buy and sell, and will buy and sell shares of Conexeu Sciences Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the Company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned Company; this is a paid advertisement.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Specific risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, but are not limited to, the following: Conexeu Sciences Inc. is a preclinical-stage company, and preclinical results generated through the program at the Wake Forest Institute for Regenerative Medicine may not be predictive of results in future clinical studies or in human patients; the Company’s anticipated 510(k) submission in early 2027 is subject to regulatory review, and there is no assurance that clearance or approval will be granted on the anticipated timeline, on favorable terms, or at all; there is no guarantee that the preclinical program at WFIRM will generate data sufficient to support clinical investigation, or that any future clinical investigation will demonstrate safety and efficacy adequate to support commercialization; although the Company holds issued patents in the United States, European Union, Japan, and Australia, there is no assurance that such patents will be upheld, will provide adequate protection against competitors, or that third parties will not assert intellectual property claims against the Company; the markets the Company targets — including breast reconstruction, wound care, periodontal applications, body contouring, and veterinary medicine — are served by established, well-capitalized competitors with significantly greater resources, clinical data, regulatory approvals, and market presence than the Company currently possesses; the Company’s preclinical program depends on its collaboration with WFIRM and ReMDO, and any disruption to these relationships could materially affect the Company’s development timeline; there is no assurance that the Company will be able to manufacture its products at commercial scale, at acceptable cost, or in compliance with applicable quality and regulatory standards; even if the Company’s products receive regulatory clearance, there is no assurance that surgeons, healthcare systems, or patients will adopt them; market growth projections for the regenerative medicine sector — including estimates of expansion from approximately $47.4 billion in 2025 to approximately $230.4 billion by 2034 — are forward-looking projections prepared by third parties and are subject to significant uncertainty; and the size and persistence of demand in the GLP-1-driven skin laxity category depends on continued adoption of GLP-1 therapies, patient outcomes, and reimbursement dynamics, all of which are subject to change.

In preparing this publication, MIQ has relied upon information supplied by its sources. Sources and MIQ have not independently verified any of the information supplied and MIQ makes no representation or warranty, express or implied, as to the accuracy or completeness of such information.

Furthermore, MIQ is not responsible for any errors or omissions or for the results obtained from the use of such information. Investors should conduct their own due diligence with respect to Conexeu Sciences Inc. and all other companies mentioned in this article. None of the content issued by MIQ constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by MIQ. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeliness of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed.

Issued on behalf of Conexeu Sciences Inc. by Equity Insider / MIQ.

Logo – https://mma.prnewswire.com/media/2840019/5997502/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-body-as-blueprint-a-recently-public-biotech-bets-that-regrown-tissue-beats-replacement-parts-302787547.html

SOURCE Equity Insider